Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides

J Invest Dermatol. 2000 Nov;115(5):805-12. doi: 10.1046/j.1523-1747.2000.00143.x.

Abstract

We topically applied 20 nucleotide phosphorothioate intercellular adhesion molecule-1 anti-sense oligodeoxynucleotide in a cream formulation. It effectively inhibited tumor necrosis factor-alpha-induced expression of intercellular adhesion molecule-1 in human skin transplanted on severe compromised immunodeficient mice. The effects were concentration dependent, sequence specific, and resulted from reduction of intercellular adhesion molecule-1 mRNA levels in the skin. Intravenous administration of the drug did not show pharmacologic effects, probably due to insufficient drug concentrations in skin. Topical delivery, however, produced a rapid and a significantly higher accumulation of oligodeoxynucleotide in the epidermis and dermis. The results strongly suggest that topically applied anti-sense oligonucleotides can be delivered to target sites in the skin and may be of considerable value in the treatment of psoriasis and other inflammatory skin disorders.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Topical
  • Animals
  • Humans
  • Intercellular Adhesion Molecule-1 / biosynthesis*
  • Intercellular Adhesion Molecule-1 / genetics
  • Mice
  • Mice, Hairless
  • Oligonucleotides, Antisense / administration & dosage*
  • Oligonucleotides, Antisense / pharmacology
  • RNA, Messenger / metabolism
  • Skin / chemistry*
  • Skin / drug effects
  • Skin Transplantation / physiology

Substances

  • Oligonucleotides, Antisense
  • RNA, Messenger
  • Intercellular Adhesion Molecule-1